Trending

AveXis

AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available

AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available

Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma

X

AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available

https://pharmaphorum.com/news/avexis-rules-out-eu-compassionate-use-of-sma-gene-therapy-zolgensma/

Gene Therapy Analytical Development

Gene Therapy Analytical Development

In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit

X

Gene Therapy Analytical Development

https://pharmaphorum.com/events/gene-therapy-analytical-development/

Weekly roundup: More questions for Novartis in Zolgensma scandal

Weekly roundup: More questions for Novartis in Zolgensma scandal

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for

X

Weekly roundup: More questions for Novartis in Zolgensma scandal

https://pharmaphorum.com/views-and-analysis/weekly-roundup-more-questions-for-novartis-in-zolgensma-scandal/

PTC shares soar after SMA drug data impresses market

PTC shares soar after SMA drug data impresses market

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on

X

PTC shares soar after SMA drug data impresses market

https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/

AveXis surges on promising gene therapy

AveXis surges on promising gene therapy

Company will discuss next steps with FDA shortly

X

AveXis surges on promising gene therapy

https://pharmaphorum.com/news/avexis-surges-promising-gene-therapy/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com